ATE323702T1 - Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität - Google Patents

Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Info

Publication number
ATE323702T1
ATE323702T1 AT03766443T AT03766443T ATE323702T1 AT E323702 T1 ATE323702 T1 AT E323702T1 AT 03766443 T AT03766443 T AT 03766443T AT 03766443 T AT03766443 T AT 03766443T AT E323702 T1 ATE323702 T1 AT E323702T1
Authority
AT
Austria
Prior art keywords
tie2
tek
pyrimidines
activity
condensed pyridines
Prior art date
Application number
AT03766443T
Other languages
English (en)
Inventor
Richard William Arthur Luke
Clifford David Jones
William Mccoull
Barry Raymond Hayter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218168A external-priority patent/GB0218168D0/en
Priority claimed from GB0312356A external-priority patent/GB0312356D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE323702T1 publication Critical patent/ATE323702T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
AT03766443T 2002-08-06 2003-08-01 Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität ATE323702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0218168A GB0218168D0 (en) 2002-08-06 2002-08-06 Compounds
GB0312356A GB0312356D0 (en) 2003-05-30 2003-05-30 Compounds

Publications (1)

Publication Number Publication Date
ATE323702T1 true ATE323702T1 (de) 2006-05-15

Family

ID=31497259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766443T ATE323702T1 (de) 2002-08-06 2003-08-01 Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Country Status (15)

Country Link
US (1) US7427616B2 (de)
EP (1) EP1537112B1 (de)
JP (1) JP2005538118A (de)
KR (1) KR20050067383A (de)
AR (1) AR041189A1 (de)
AT (1) ATE323702T1 (de)
AU (1) AU2003246972A1 (de)
BR (1) BR0313078A (de)
CA (1) CA2494421A1 (de)
DE (1) DE60304718T2 (de)
IL (1) IL166521A0 (de)
MX (1) MXPA05001389A (de)
NO (1) NO20050418L (de)
TW (1) TW200407116A (de)
WO (1) WO2004013141A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1687309A1 (de) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidinverbindungen, die sich zur behandlung von krebs eignen
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
US7517888B2 (en) 2004-04-28 2009-04-14 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
CA2566160C (en) * 2004-05-27 2011-01-18 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
CA2569887A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200615268A (en) * 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
KR20070049655A (ko) 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
ES2465469T3 (es) 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
AU2006330587B2 (en) * 2005-12-23 2012-12-13 Glaxosmithkline Llc Azaindole inhibitors of aurora kinases
AU2007240568A1 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
CN101965350A (zh) 2008-01-11 2011-02-02 纳科法尔马有限公司 作为抗癌剂的新的吡唑并[3,4-d]嘧啶衍生物
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2731228A1 (en) 2008-07-22 2010-01-28 Biocryst Pharmaceuticals, Inc. Synthetic intermediates and processes
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
EP2603216A4 (de) * 2010-08-11 2013-12-18 Millennium Pharm Inc Heteroaryle und verwendungen davon
US8362004B2 (en) 2010-09-08 2013-01-29 Bristol-Myers Squibb Company Piperazine analogs as broad-spectrum influenza antivirals
EA201390476A1 (ru) 2010-09-28 2013-08-30 Бристол-Майерс Сквибб Компани Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
EP2733146A1 (de) * 2012-11-20 2014-05-21 KTB Tumorforschungsgesellschaft mbH Thioetherderivate als Proteinkinase-Inhibitoren
CN104936963B (zh) * 2012-11-20 2017-11-28 普罗齐纳斯有限公司 作为蛋白激酶抑制剂的硫醚衍生物
KR20160030565A (ko) 2013-07-15 2016-03-18 바스프 에스이 살충제 화합물
CA2921199A1 (en) * 2013-08-27 2015-03-05 Bristol-Myers Squibb Company Ido inhibitors
WO2016100495A1 (en) * 2014-12-17 2016-06-23 Duquesne University Of The Holy Spirit CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS
EP3632908A1 (de) 2018-10-02 2020-04-08 Inventiva Inhibitoren der yap / taz-tead-interaktion und ihre verwendung bei der behandlung von krebs
CN113272308A (zh) * 2018-11-20 2021-08-17 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD287503A5 (de) 1988-06-13 1991-02-28 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 4-amino-2-mercapto-thieno-/2,3-d/pyrimidinen bzw. 4-amino-2-alkylthio-thieno/2,3-d/-pyrimidinen
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
CA2263838A1 (en) 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
DE69815317T2 (de) 1997-03-19 2005-04-07 Abbott Gmbh & Co. Kg Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
AU3859999A (en) 1998-05-14 1999-11-29 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
HUP0200355A3 (en) 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
ID29028A (id) 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1175419B1 (de) 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Arylsulfonyle als faktor xa inhibitoren
AR029347A1 (es) 1999-04-02 2003-06-25 Euro Celtique Sa Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
EP1181296A1 (de) 1999-06-03 2002-02-27 Abbott Laboratories Zelladhäsionshemmende entzündungshemmende verbindungen
DE60037455T2 (de) 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
RU2002110295A (ru) 1999-09-17 2003-12-10 Милленниум Фармасьютикалс, Инк. (Us) Ингибиторы фактора Ха
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
AU780052B2 (en) 1999-09-17 2005-02-24 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
CA2395564A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
WO2001044259A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Purine derivatives
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
JP2004514405A (ja) 2000-03-29 2004-05-20 アボット　ゲーエムベーハー　ウント　カンパニー　カーゲー Ｔｉｅ−２阻害薬の特定方法
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
EP1345966A2 (de) 2000-09-08 2003-09-24 Glaxo Group Limited Kristallisierte zytoplasmatische tie2 rezeptor-tyrosinkinase domäne und verfahren zur feststellung und zum design ihrer modulatoren
US20020146472A1 (en) 2000-11-15 2002-10-10 Chen Kuang Yu Black tea extract for prevention of disease
WO2002044156A2 (en) 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
AU2002305205A1 (en) 2001-04-20 2002-11-05 Jingrong Cao 9-deazaguanine derivatives as inhibitors of gsk-3
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
DE60228295D1 (de) 2001-09-21 2008-09-25 Smithkline Beecham Corp Chemische verbindungen
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
AU2002356301A1 (en) 2001-12-21 2003-07-15 Cancer Research Technology Ltd. 3,4-diarylpyrazoles and their use in the therapy of cancer
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
CN100386328C (zh) 2002-03-07 2008-05-07 霍夫曼-拉罗奇有限公司 双环吡啶和嘧啶p38激酶抑制剂

Also Published As

Publication number Publication date
DE60304718T2 (de) 2007-04-26
JP2005538118A (ja) 2005-12-15
US20050256140A1 (en) 2005-11-17
DE60304718D1 (de) 2006-05-24
CA2494421A1 (en) 2004-02-12
US7427616B2 (en) 2008-09-23
BR0313078A (pt) 2005-07-12
AU2003246972A1 (en) 2004-02-23
KR20050067383A (ko) 2005-07-01
TW200407116A (en) 2004-05-16
EP1537112B1 (de) 2006-04-19
EP1537112A1 (de) 2005-06-08
IL166521A0 (en) 2006-01-15
WO2004013141A1 (en) 2004-02-12
NO20050418L (no) 2005-04-28
MXPA05001389A (es) 2005-04-28
AR041189A1 (es) 2005-05-04

Similar Documents

Publication Publication Date Title
ATE323702T1 (de) Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
DE50305279D1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
DE60333166D1 (de) Pyridin- und pyrimidin-derivate
IS6518A (is) Pyridín, pyrimidín, pyrazín og tríazín setin með arýl og notkun þeirra
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
ATE402705T1 (de) Pyrimidine mit tie2 (tek) aktivität
ATE434610T1 (de) Aryl substituierte pyrimidine und deren verwendung
ATE410429T1 (de) Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
IL176806A0 (en) Novel pyridine derivative and pyrimidine derivative (2)
NO20021520D0 (no) Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet
NO20042676L (no) 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav
PL370480A1 (en) Aminopyrimidines and pyridines
ATE377591T1 (de) Pyrimidinderivate und deren verwendung als cb2- modulatoren
DE602004006383D1 (de) Die hiv-replikation inhibierende pyrimidine und triazine
ATE362313T1 (de) Nicotinsäure-heterocyclyl-amide und analoge pyrimidin-derivate als schädlingsbekämpfungsmittel
ATE415970T1 (de) Pyrimidine mit tie2 (tek) aktivität
IL174497A0 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
DE69837621D1 (de) Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel
DE69627062D1 (de) Herbizide 2,6-disubstituierte Pyridine und 2,4-disubstituierte Pyrimidine
NO20035797L (no) 6-[2-(fosfonometoksy)alkoksy]pyrimidinderivater med antiviral aktivitet
DE502004002570D1 (de) 2-substituierte pyrimidine
ZA200500863B (en) Condensed pyridines and pyrimidines with Tie2 (tek) activity.
DE50106542D1 (de) Substituierte 3,4-dihydro-pyrido[1,2-a]pyrimidine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties